Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
2.900
+0.110 (3.94%)
Dec 20, 2024, 4:00 PM EST - Market closed
Prime Medicine Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 13.13, with a low estimate of 10 and a high estimate of 18. The average target predicts an increase of 352.76% from the current stock price of 2.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $10 | Buy | Initiates | $10 | +244.83% | Dec 10, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +520.69% | Dec 3, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 → $15 | Strong Buy | Maintains | $17 → $15 | +417.24% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +244.83% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +244.83% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
935.71K
Revenue Next Year
4.93M
from 935.71K
Increased by 426.55%
EPS This Year
-1.67
from -2.18
EPS Next Year
-1.35
from -1.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.3M | 26.3M | 194.3M | |||
| Avg | 935,707 | 4.9M | 25.1M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 2,705.4% | 3,842.6% | |||
| Avg | - | 426.6% | 409.8% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.24 | -0.79 | -0.70 | |||
| Avg | -1.67 | -1.35 | -1.39 | |||
| Low | -1.77 | -1.89 | -2.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.